NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Mind Medicine (MindMed) Inc. (MNMD) Stock Analysis

Mind Medicine (MindMed) Inc. (MNMD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MNMD

$18.09

−$0.23 (−1.26%)

Last trade March 17, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MNMD with… →

MNMD Key Statistics

As of Mar 17, 2026
Trading
Open
$18.29
Previous Close
$18.32
Day's Range
18.05–18.74
52-Week Range
4.70–18.12
Volume
1.47M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.62
Valuation
Market Cap
$1.46B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.98
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+179.60%
Dividend and dates
Avg Volume
2.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MNMD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+35.10%
2025+92.39%
2024 (partial year)−0.78%

As of March 17, 2026.

MNMD Valuation vs Biotechnology Median

Median of 656 stocks
MetricMNMDBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Mind Medicine (MindMed) Inc. (MNMD) is capitalised at $1.46B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 74.

Over the past 52 weeks the price has ranged from $4.70 to $18.12. MNMD last closed at $18.09 on March 17, 2026. That is −$0.23 (−1.26%) against the previous close. The latest close sits 284.89% above that 52-week low.

Financial Health

The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.98.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +179.60%. The reported beta is 2.62. Daily returns over the trailing 1 year annualize to a volatility of 66.26%.

Growth & Income

The record shows no dividend for MNMD.

The record holds one complete calendar year, 2025, which returned +92.39%. So far in 2026 the price is +35.10%.

Peer Comparison

Mind Medicine (MindMed) Inc. (MNMD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Mind Medicine (MindMed) Inc. MNMD $1.46B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Mind Medicine (MindMed) Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of March 17, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Visit website →